Nature Reviews PrimeView on T2D
A new PrimeView infographic in Nature Reviews maps type 2 diabetes as a global epidemic driven by obesity and responsible for roughly 9% of deaths — it lays out epidemiology, insulin resistance + β-cell dysfunction, and diagnosis via HbA1c and OGTT in one visual package (x.com). The infographic also highlights a shift toward holistic care and digital monitoring—CGM and remote analytics are flagged as core tools for precision management (x.com).
PrimeView was published as DOI 10.1038/s41572-026-00694-x and is presented as an infographic companion to the full Nature Reviews Disease Primers article (DOI 10.1038/s41572-026-00687-w), released March 19, 2026. (nature.com; nature.com) The Primer’s author list names Melanie J. Davies and Ildiko Lingvay as lead contributors, with coauthors from institutions including the University of Leicester, UT Southwestern Medical Center and Scripps Health. (nature.com) PrimeView reproduces global burden estimates showing an estimated 828 million adults with diabetes in 2022 and reports sex-specific prevalence of 13.9% in women and 14.3% in men. (nature.com) The infographic notes that about 40% of people with diabetes are undiagnosed worldwide and highlights a rapid rise in early-onset diagnoses (age <40), particularly in low- and middle-income countries. (nature.com) For diagnostic clarity, PrimeView recommends adding islet autoantibody or C‑peptide testing when differentiation from type 1 or monogenic diabetes is uncertain and advocates using ethnicity-specific BMI thresholds for targeted screening. (nature.com) In its Outlook panel PrimeView lists specific investigational therapeutics—including mazdutide, survodutide, retatrutide, ecnoglutide and orforglipron alongside established GLP‑1 agents such as semaglutide and tirzepatide—and diagrams several agents as nearing phase III or licensing within the next decade. (nature.com)
